Connecting the Dots: An update on the recent CKD, MASLD, and Obesity Pharmacotherapy Guidelines

Faculty:

Sue D. Pedersen, M.D (Endocrinologist)

James Kim, MBBCh (Family Physician)

Phil McFarlane, MD (Nephrologist)

Giada Sebastiani, MD (Hepatologist)

LEARNING OBJECTIVES

After attending this program, participants will be able to:

1. Define the characteristics of the cardiometabolic patient and identify overlapping risk factors
across diabetes, CKD, MASLD, and obesity in primary care.

2. Interpret and integrate the latest Diabetes Canada and Obesity Canada clinical practice
guideline updates related to CKD, MASLD, and obesity pharmacotherapy.

3. Recognize the expanding role of GLP-1–based therapies in the holistic care of patients with
interconnected cardiometabolic conditions.